Stock LYEL LYELL IMMUNOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Lyell Immunopharma, Inc.

Equities

LYEL

US55083R1041

Real-time Estimate Cboe BZX
Other stock markets
 03:07:39 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.175 USD -1.14% Intraday chart for Lyell Immunopharma, Inc. -2.47% +12.11%
Mar. 04 North American Morning Briefing : Stock Futures -2- DJ
Feb. 28 Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
LYELL IMMUNOPHARMA, INC. Stock Lyell Immunopharma, Inc.
+12.11% 561M
C
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.12% 103B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.69% 95.71B
B+
ARGENX SE Stock argenx SE
+1.69% 22.02B
B
BIONTECH SE Stock BioNTech SE
-17.05% 20.9B
B+
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.21B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.81% 15.52B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.34% 13.86B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.69% 12.04B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LYEL Stock
  4. Ratings Lyell Immunopharma, Inc.